Page 2 - Trial Protocol News Today

This randomized clinical trial examined outcomes of inguinal hernia surgery performed by associate clinicians vs nonspecialist medical doctors among men in Sier

This report, the Consolidated Standards of Reporting Trials (CONSORT)–Outcomes 2022 extension, is a consensus statement on the standards for reporting outcomes

This clinical trial compares the efficacy of nitric oxide applied into the cardiopulmonary bypass oxygenator vs standard care on ventilator-free days in childre

(PGH Facebook Page/Manila Bulletin File Photo) DOST-MIRDC Executive Director Robert O. Dizon disclosed this at the sidelines of DOST Secretary Fortunato “Boy” T. de la Peña’s weekly report on Friday, May 7. “Nung April nabuo na ang medical team na magsasagawa ng trial na ito. Maayos na rin ang susundin nila na safety protocol. Hinihintay na lang ngayon na bumaba ang kaso ng COVID (coronavirus disease) kasi gagawin natin ang trial sa PGH (Last April, the medical team that will conduct...

OstreaVent I and II (Screenshot from DOSTv Facebook Page) DOST Secretary Fortunato “Boy” T. de la Peña said OstreaVent II was developed by the agency’s Metals Industry Research and Development Center (MIRDC) in partnership with the Breath of Life Foundation Inc. “It can be used by both infant and adult; it is both pressure- and volume-controlled; it measures tidal volume, and it has bacterial and viral filters,” he said during his weekly report on Friday. He noted that the clinical...

The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use. The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic w...

Share this article HOUSTON, Feb. 18, 2021 /PRNewswire/ -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upco...

Updated Jan 03, 2021 | 13:22 IST The drug regulator has given a conditional nod to SIIs Covishield and Bharat Biotechs Covaxin. Permission was also granted for Cadila Healthcares Phase 3 trials. Representational Image&nbsp Drug Regulator accepts SECs recommendations, gives conditional nod for Covishield, Covaxin PM hails the nod for SII & Bharat Biotech vaccines as a decisive turning point in fight against COVID 2021 promises to the year of vaccination in India and...

URL copied Expert panel recommends granting restricted emergency use approval for COVAXIN. A day after a government panel recommended to grant emergency use approval for the Oxford-AstraZenecas Covishield vaccine for coronavirus, an expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotechs indigenously developed COVID-19 vaccine — Covaxin, ANI reported quoting government sources. The Subject Expert Committee of Central...